阿奇霉素在慢性鼻窦炎中的作用机制包括上皮屏障修复和1型炎症减轻
本研究通过体外伤口愈合模型和体内转录组分析验证阿奇霉素在慢性鼻窦炎(CRS)中的作用机制。体外实验显示阿奇霉素提高CRS患者原代鼻上皮细胞伤口愈合速率并预防金黄色葡萄球菌对上皮修复的负面影响;体内转录组显示1型炎症通路下调、细胞周期恢复通路上调,最大效应见于1型炎症增强水平高的患者,提示阿奇霉素可能为手术无反应CRS患者的新治疗选择。
要点
- 阿奇霉素提高CRS患者原代鼻上皮细胞伤口愈合速率并预防金黄色葡萄球菌对上皮修复的负面影响
- 体内应答与1型炎症通路下调及细胞周期恢复通路上调相关
- 1型炎症增强水平高的患者效应最大,阿奇霉素可能为手术无反应CRS的新选择
核心结论
- 恢复健康上皮功能可能代表阿奇霉素在CRS中的主要作用方式。
- 体外模型显示上皮修复增强,体内转录组显示1型炎症通路下调伴DNA修复和细胞周期通路上调。
- 1型炎症增强水平高的患者效应最大,提示阿奇霉素可能为手术无反应CRS患者的新治疗选择。
研究设计与样本
- 研究在学术医疗中心进行,采用体外伤口愈合模型和体内转录组分析。
- 体外使用CRS患者原代鼻上皮细胞(pNEC)验证阿奇霉素对上皮修复速度的影响。
- 体内对安慰剂对照试验中手术无反应的CRS患者治疗前后鼻刷检样本进行转录组分析以识别相关通路。
主要发现
- 阿奇霉素提高CRS pNEC的伤口愈合速率并预防金黄色葡萄球菌对上皮修复的负面影响。
- 体内对阿奇霉素的应答与1型炎症通路下调和细胞周期恢复通路上调相关。
- 1型炎症增强水平高的患者中效应最大。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Previous in vitro transcriptomic profiling suggests azithromycin exerts its effects in patients with chronic rhinosinusitis (CRS) via modulation of type 1 inflammation and restoration of epithelial barrier function. We wished to verify these postulated effects using in vitro models of epithelial repair and in vivo transcriptional profiling. STUDY DESIGN: Functional effects of azithromycin in CRS were verified using in vitro models of wounding. The mechanism of the effect of azithromycin was assessed in vivo using transcriptomic profiling. SETTING: Academic medical center. METHODS: Effects of azithromycin on the speed of epithelial repair were verified in a wounding model using primary nasal epithelial cells (pNEC) from CRS patients. Nasal brushings collected pre-and posttreatment during a placebo-controlled trial of azithromycin for CRS patients unresponsive to surgery underwent transcriptomic profiling to identify implicated pathways. RESULTS: Administration of azithromycin improved the wound healing rates in CRS pNECs and prevented the negative effect of Staphylococcus aureus on epithelial repair. In vivo, response to azithromycin was associated with downregulation in pathways of type 1 inflammation, and upregulation of pathways implicated in the restoration of the cell cycle. CONCLUSION: Restoration of healthy epithelial function may represent a major mode of action of azithromycin in CRS. In vitro models show enhanced epithelial repair, while in vivo transcriptomics shows downregulation of pathways type 1 inflammation accompanied by upregulation of DNA repair and cell-cycle pathways. The maximal effect in patients with high levels of type 1-enhanced inflammation suggests that azithromycin may represent a novel therapeutic option for surgery-unresponsive CRS patients.
引用
- Renteria AE, Valera FCP, Maniakas A, et al. Azithromycin Mechanisms of Action in CRS Include Epithelial Barrier Restoration and Type 1 Inflammation Reduction. Otolaryngol Head Neck Surg. 2023. PMID: 37125631. doi:10.1002/ohn.355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。